IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA
02 avr. 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, April 02, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced it has received a Complete...
IntelGenx Announces Montreal’s Douglas Mental Health University Institute as Ninth Montelukast VersaFilm™ Phase 2a Clinical Trial Site
14 févr. 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 14, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that, subject to final research...
IntelGenx Granted Japanese Patent for RIZAPORT® VersaFilm™
11 févr. 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 11, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has received a Decision...
IntelGenx Strengthens Senior Management Team
07 févr. 2019 16h00 HE
|
IntelGenx Technologies Corp.
SAINT-LAURENT, Québec, Feb. 07, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT), today announced that it has strengthened its management team with the...
IntelGenx Facility Undergoes U.S. FDA Pre-Approval Inspection Related to RIZAPORT® NDA
30 janv. 2019 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Jan. 30, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the U.S. Food and Drug...
IntelGenx Provides Update on Cannabis-Infused VersaFilm™ Program Following Recently Proposed Amendments to the Cannabis Act
14 janv. 2019 08h00 HE
|
IntelGenx Technologies Corp.
Working with partner Tilray®, IntelGenx aims to launch oral film products in late-2019 SAINT LAURENT, Quebec, Jan. 14, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT)...
IntelGenx Partners with Gensco® Pharma to Market RIZAPORT® in the United States
12 déc. 2018 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Dec. 12, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced the execution of a definitive...
IntelGenx Begins Montelukast VersaFilm™ Dosing in Patients with Mild to Moderate Alzheimer’s Disease in Phase 2a Study
27 nov. 2018 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 27, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that patient dosing has commenced in the Phase 2a...
IntelGenx Announces FDA’s Acceptance of Resubmission of New Drug Application for RIZAPORT®
20 nov. 2018 08h00 HE
|
IntelGenx Technologies Corp.
- PDUFA Goal Date of April 1, 2019 - SAINT LAURENT, Quebec, Nov. 20, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that its...
IntelGenx Reports Third Quarter 2018 Financial Results
08 nov. 2018 16h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 08, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today reported financial results for the third quarter...